/

Sociétés

Da

Non vérifié

Daiichi Sankyo

Ce que nous écrivons

IndustrieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

82 communiqués de presse

Voir tous les communiqués de presse

22/01/2026

Oncologie

Santé

Science

Industrie pharmaceutique

Biotechnologie

Marché du travail

Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe

Source

Émetteur

1.00

0

19/01/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Industrie

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Source

Émetteur

1.00

0

13/01/2026

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé Publique

Santé

Médecine - Divers

Industrie

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Source

Émetteur

1.00

0

07/01/2026

Oncologie

Santé

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Marché du travail

Industrie

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

Source

Émetteur

1.00

0

22/12/2025

Industrie

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé Publique

Santé

Médecine - Divers

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

Source

Émetteur

1.00

0

22/12/2025

Industrie

Oncologie

Santé

Hygiène alimentaire

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

Source

Émetteur

1.00

0

18/12/2025

Industrie

Oncologie

Santé

Médecine - Divers

Santé Publique

Industrie pharmaceutique

Biotechnologie

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Source

Émetteur

1.00

0

15/12/2025

Industrie

Science

Industrie pharmaceutique

Oncologie

Vitrines/Shopping

Biotechnologie

Médecine - Divers

Santé

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Source

Émetteur

1.00

0

09/12/2025

Industrie

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

Science

Vitrines/Shopping

Médecine - Divers

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

Source

Émetteur

1.00

0

08/12/2025

Biotechnologie

Industrie pharmaceutique

Santé

Industrie

Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0